BLUE News and Press, bluebird bio Inc. From 02/25/21

The New England Journal of Medicine has published the Phase 2 study results for CAR T cell immunotherapy, idecabtagene vicleucel (ide-cel; bb2121) developed by bluebird bio ([[BLUE]] +4.4%) and Bristol Myers Squibb’s ([[BMY]] +0.8%) for a certain group of adults with multiple myeloma.T...

First pivotal study of BCMA-directed CAR T cell therapy in triple-class exposed relapsed and refractory multiple myeloma Biologics License Application (BLA) for ide-cel was accepted by FDA for Priority Review, with a target action date of March 27, 2021 Results from ...

The share price of bluebird bio (NASDAQ: BLUE) is down a staggering 70% over the past year. The company has encountered more roadblocks than expected on its path to find cures for sickle cell disease (SCD) and beta thalassemia. Worldwide, more than 300,000 babies are born with...

bluebird bio (BLUE) Q4 2020 results missed analyst estimates on both EPS and revenue.Revenue increased modestly quarter over quarter from $10M to $10M and the EPS loss narrowed to ($3.01) from ($4.04).Operating expenses for the quarter were $214.7M and $873.8M million for the year.R&D exp...

bluebird bio (BLUE): Q4 GAAP EPS of -$3.01 misses by $0.05.Revenue of $10.71M (+7.2% Y/Y) misses by $4.3M.Shares +1.1%.Press Release For further details see: bluebird bio EPS misses by $0.05, misses on revenue

bluebird bio, Inc. (NASDAQ:BLUE) today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2020 and shared recent operational progress. “For over ten years, bluebird bio has been pioneering gene therapies for patients wit...

The gene editing sector remains red-hot as the promise to transform the way disease is treated. CRISPR Therapeutics seems primed to exploit the technology for outsized share gains. The company faces some intense challenges as will be detailed below. For further details see: ...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the 10 th Annual SVB Leerink Global Healthcare Conference, Thursday, February 25, at 12:00 p.m. ET. To access the live webcast of bluebird bio’s presentation, please ...

The decision by bluebird bio ([[BLUE]] -3.4%) to suspend two clinical trials involving its lentiviral vector-based gene therapy candidate, LentiGlobin hurt other biotech developers such as Rocket Pharmaceuticals ([[RCKT]] +0.0%) whose portfolio have lentiviral vector-based experimental t...

AVRO dropped after bluebird's lentiglobin trials were halted because of AML/MDS concerns. Both therapies use Lentiviral vectors, hence the concern. However, Kymriah also uses Lentiviral vectors, and there have been no reports of secondary malignancies. For further details se...